Patents by Inventor Kumaravel Selvakumar

Kumaravel Selvakumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200138789
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: January 2, 2020
    Publication date: May 7, 2020
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Patent number: 10576062
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: March 3, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Publication number: 20190270741
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: September 5, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Pratik DEVASTHALE, Fang MOORE, Guohua ZHAO, Susan Nicole PIENIAZEK, Kumaravel SELVAKUMAR, Suresh DHANUSU, Manoranjan PANDA, Lawrence R. MARCIN
  • Publication number: 20190263808
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: August 29, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guohua ZHAO, Pratik DEVASTHALE, Xiang-Yang YE, Kumaravel SELVAKUMAR, Suresh DHANUSU, Palanikumar BALASUBRAMANIAN, Leatte R. GUERNON, Rita CIVIELLO, Xiaojun HAN, Michael Frederick PARKER, Swanee E. JACUTIN-PORTE
  • Publication number: 20180333395
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 22, 2018
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Patent number: 10071078
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: September 11, 2018
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Publication number: 20170360759
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: June 20, 2017
    Publication date: December 21, 2017
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun LI, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Patent number: 8507683
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: August 13, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Kumaravel Selvakumar
  • Publication number: 20120309770
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: December 5, 2011
    Publication date: December 6, 2012
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Kumaravel Selvakumar
  • Patent number: 7268233
    Abstract: The invention relates to novel monocarbene complexes of nickel, palladium or platinum with electron-deficient olefin ligands, to their preparation and to their use in the homogeneous catalysis of organic reactions.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: September 11, 2007
    Assignee: Umicore AG & Co. KG
    Inventors: Ralf Karch, Oliver Briel, Bernd Kayser, Matthias Beller, Kumaravel Selvakumar, Anja Frisch, Alexander Zapf
  • Publication number: 20060122398
    Abstract: The invention relates to novel monocarbene complexes of nickel, palladium or platinum with electron-deficient olefin ligands, to their preparation and to their use in the homogeneous catalysis of organic reactions.
    Type: Application
    Filed: August 7, 2003
    Publication date: June 8, 2006
    Inventors: Ralf Karch, Oliver Briel, Bernd Kayser, Matthias Beller, Kumaravel Selvakumar, Anja Frisch, Alexander Zapf